- freely available
Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines
AbstractThe development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.
Share & Cite This Article
Berzi, A.; Varga, N.; Sattin, S.; Antonazzo, P.; Biasin, M.; Cetin, I.; Trabattoni, D.; Bernardi, A.; Clerici, M. Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines. Viruses 2014, 6, 391-403.View more citation formats
Berzi A, Varga N, Sattin S, Antonazzo P, Biasin M, Cetin I, Trabattoni D, Bernardi A, Clerici M. Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines. Viruses. 2014; 6(2):391-403.Chicago/Turabian Style
Berzi, Angela; Varga, Norbert; Sattin, Sara; Antonazzo, Patrizio; Biasin, Mara; Cetin, Irene; Trabattoni, Daria; Bernardi, Anna; Clerici, Mario. 2014. "Pseudo-Mannosylated DC-SIGN Ligands as Potential Adjuvants for HIV Vaccines." Viruses 6, no. 2: 391-403.
Notes: Multiple requests from the same IP address are counted as one view.